Addition of midostaurin, a first-generation FLT3 inhibitor, to frontline induction therapy is currently a standard approach to the treatment of FLT3-mutated AML.
Venetoclax, a BCL2 inhibitor, used in combination with a HMA improved outcomes in a cohort of 9 patients with AML secondary to MPN.
AL amyloidosis patients with hematologic response and low serum free light chain levels may have longer OS.
Recent guidelines have provided additional information on the treatment, management, and risk-stratifications of acute myeloid leukemia in older patients.
Sorafenib maintenance showed positive relapse, survival, and safety outcomes for patients with FLT3-ITD acute myeloid leukemia after transplantation.
Patients with newly diagnosed AML who are ineligible for intensive chemotherapy may benefit from a 10-day course of decitabine with venetoclax.
The approval was based on data from the multicenter, randomized, double-blind, placebo-controlled, phase 3 QUAZAR study.
Investigators aimed to determine the prognostic value of WT1 expression among patients with AML who were in earlier stages of treatment.
Even after treatment with hypomethylating agents, older patients with AML still lack positive prognoses but azacitidine with venetoclax shows promise.
Combined with chemotherapy, venetoclax appears to be effective for treating AML among fit elderly patients.
